PwC

May 2023

Big Pharma M&As: Is It Worth the Trouble?

By |2024-06-07T14:30:31+02:00May 10, 2023|Blog, M&A Insights and Solutions, News|Comments Off on Big Pharma M&As: Is It Worth the Trouble?

Big Pharma M&As: A Worthwhile Challenge? Navigating the complex landscape of M&As in the pharmaceutical industry comes with unique objectives and potential benefits. But do these transactions truly drive shareholder value for the acquiring firm?

May 2023

Enhancing R&D Due Diligence in Pharma M&As: The Role of MyRBQM Portal

By |2024-06-07T15:19:19+02:00May 10, 2023|Blog, M&A Insights and Solutions, News|Comments Off on Enhancing R&D Due Diligence in Pharma M&As: The Role of MyRBQM Portal

Navigate your M&A journey confidently with Cyntegrity's MyRBQM Portal. Aspiring to hit your targets within 6-12 months? Discover how we can make it possible in R&D due diligence.

Go to Top